Back

Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking

28 August 2022 (11:50 - 12:00)
Organised by:
Congress Presentation Part of: Optimal risk factor therapy in high risk patients Tobacco ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Michael Miller

Corporal Michael J. Crescenz VA Medical Center, Philadelphia (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Ms B. Heidemann (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial
Doctor A. Sharma (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia
Doctor A. Wiegman (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia
Doctor S. Funabashi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Clinical consequences of the lipid-lowering treatment in patients with acute coronary syndrome: real-world retrospective study (LipidACS study)
Doctor J. Alarcon (Donostia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Optimal risk factor therapy in high risk patients

The Event

Event poster

ESC Congress 2022

28 August 2022 11:50 CET
You may be interested in
thumbnail
Congress Presentation
Key takeaways & practical guidance
thumbnail
Congress Presentation
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
thumbnail
Congress Session
Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources